Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Factor XIIa inhibitors
3 evidence topics · 2 sources
Garadacimab: mechanism and maintenance dosing
Garadacimab: approved population and administration
Garadacimab: guideline summary of efficacy
“It inhibits activated factor XIIa at the top of the kallikrein-kinin pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the phase 3 Vanguard trial the attack rate was reduced by 87% compared to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote